LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 106 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $157,000 | -29.9% | 133,051 | -16.2% | 0.00% | – |
Q2 2023 | $223,867 | -67.8% | 158,771 | -65.7% | 0.00% | – |
Q1 2023 | $694,326 | +24.4% | 462,884 | -3.0% | 0.00% | – |
Q4 2022 | $558,294 | +262.5% | 477,174 | +250.9% | 0.00% | – |
Q3 2022 | $154,000 | +1825.0% | 135,981 | +2657.7% | 0.00% | – |
Q2 2022 | $8,000 | -42.9% | 4,931 | -45.4% | 0.00% | – |
Q1 2022 | $14,000 | -83.9% | 9,037 | -74.6% | 0.00% | – |
Q4 2021 | $87,000 | -74.9% | 35,607 | -74.2% | 0.00% | – |
Q3 2021 | $347,000 | +951.5% | 137,858 | +1082.0% | 0.00% | – |
Q2 2021 | $33,000 | +73.7% | 11,663 | +43.4% | 0.00% | – |
Q1 2021 | $19,000 | +90.0% | 8,136 | +38.1% | 0.00% | – |
Q4 2020 | $10,000 | +66.7% | 5,891 | 0.0% | 0.00% | – |
Q3 2020 | $6,000 | +20.0% | 5,891 | 0.0% | 0.00% | – |
Q2 2020 | $5,000 | -83.9% | 5,891 | -84.1% | 0.00% | – |
Q1 2020 | $31,000 | +3.3% | 37,110 | +8.6% | 0.00% | – |
Q4 2019 | $30,000 | +100.0% | 34,175 | +119.1% | 0.00% | – |
Q3 2019 | $15,000 | – | 15,598 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,005,379 | $85,694,000 | 4.37% |
Defender Capital, LLC. | 4,798,270 | $12,707,000 | 4.13% |
Raffles Associates | 93,590 | $236,000 | 0.22% |
Prescott General Partners LLC | 1,851,851 | $4,667,000 | 0.16% |
DCF Advisers, LLC | 87,000 | $219,000 | 0.10% |
Laidlaw Wealth Management LLC | 104,841 | $264,000 | 0.07% |
Beirne Wealth Consulting Services, LLC | 45,000 | $113,000 | 0.06% |
Strategic Wealth Investment Group, LLC | 70,625 | $179,000 | 0.05% |
Fort Sheridan Advisors LLC | 47,931 | $121,000 | 0.04% |
Sightline Wealth Advisors, LLC | 14,958 | $38,000 | 0.03% |